摘要
抑制移植排斥免疫是为了使移植器官能够在受者体内长期存活，而本文试图用强化移植排斥免疫的方法来达到抗肿瘤的目的。结果表明：在实验１中用人ｋ５６２细胞强化免疫的小鼠，其存活期为４５．４±１７．６天，显著长于对照组的２２．０±１０．１天和ＢＣＧ组的２５．０±１４．０天，在实验２中用人Ｒａｊｉ细胞或异种肿瘤ＲＡ７９５肺癌细胞、大鼠脾细胞加ＢＣＧ强化免疫的昆明系小鼠，在十天后接种Ｈ２２肝癌细胞，其存活期分别为：４０．０±７．６天，４１．９±５．４天，３９．３±７．５天及４５．０天，均显著长于对照组的２５．３±６．６天（Ｐ＜０．０４），尤以大鼠脾细胞加ＢＣＧ强化免疫的昆明系小鼠预防肿瘤的效果为好，在４５天内无１只死亡，且有５／１０的小鼠出现肿瘤消退或局限的现象。在接种Ｈ２２肝癌细胞后第４５天处死荷瘤鼠，取肝、脾及胸腺称重，各组间肝、脾及胸腺重量无统计学差别（Ｐ＞０．０５）。提示强化移植排斥免疫不影响荷瘤鼠的主要免疫器官。
Generally, in order to prevent rejection of grafts, immune inhibitors such as CsA are used to suppress lymphocytes function of recipients. But in this report we transplanted xenogeneic spleen cills or tumor cells with BCG on mice, by means of this to suppress tumor growth of recipient mice. The results showed that the survial time of the tumor bearing mice with ERI were significantly longer than of control group and suggest that the ERI might be used as a new metod of immunotherapy to treat and prevent cancer.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
1996年第4期206-208,共3页
Cancer Research on Prevention and Treatment
关键词
移植排斥
免疫
肝肿瘤
Enhanced Transplant Regection
Xenogeneic Tumor Cells
Rat Spleen Cells
H22 Hepatic Carcinoma
